Brand / Generic Name:
Modified release aqueous suspension for intramuscular injection
RISPERDAL CONSTA® is indicated for:
- Treatment of schizophrenia and related psychoses.
- Adjunctive maintenance treatment with lithium or sodium valproate in treatment refractory patients with bipolar I disorder who have at least 4 relapses in a 12 month period.
- Monotherapy for maintenance treatment to prevent the recurrence of manic or mixed episodes of bipolar I disorder in patients with a manic or mixed episode, following stabilisation with oral risperidone.